Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
12 juin 2017 08h30 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
10 juin 2017 13h00 HE
|
Zafgen, Inc.
-Successful Phase 1 Clinical Trial Garners Late-Breaking ADA Presentation and Supports Advancement to Phase 2 Development- -ZGN-1061 Treatment Improves Glycemic Control and Body Weight in Preclinical...
Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions
05 juin 2017 08h15 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL and AUSTIN, TX; , June 05, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) today announced that data from the company’s non-aqueous, room temperature stable, ready to use...
PTS Diagnostics will Present at the American Diabetes Association’s (ADA) 76th Scientific Sessions
09 juin 2016 06h00 HE
|
PTS Diagnostics
INDIANAPOLIS, June 09, 2016 (GLOBE NEWSWIRE) -- PTS Diagnostics, the U.S.-based manufacturer of point-of-care blood testing devices including the CardioChek® and A1CNow® systems, will exhibit and...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
16 août 2015 20h28 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
Type 2 Diabetes Trial Results Published In Diabetes Care
22 juil. 2015 19h17 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 22, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
08 juin 2015 21h12 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
18 mai 2015 05h39 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment...
Type 2 Diabetes Trial Results Presented by Study Investigators at American Diabetes Association Annual Meeting
18 juin 2014 23h19 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 18, 2014 (GLOBE NEWSWIRE) -- Results from the Phase 2 trial of Mesoblast's proprietary adult stem cells in type 2 diabetes patients have been presented by Jay...
Keller Rohrback L.L.P. Investigates Telemarketer InfoCision Management Corporation Regarding Allegedly False and Misleading Donation Solicitations
19 oct. 2012 18h51 HE
|
Keller Rohrback L.L.P.
SEATTLE, Oct. 19, 2012 (GLOBE NEWSWIRE) -- Attorney Advertising Material. Keller Rohrback announces its investigation of InfoCision Management Corporation ("InfoCision" or the "Company"), an...